^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

PRAME expression

i
Other names: PRAME, Preferentially Expressed Antigen In Melanoma, Melanoma Antigen Preferentially Expressed In Tumors, Preferentially Expressed Antigen Of Melanoma, Opa-Interacting Protein 4, Cancer/Testis Antigen 130, OIP-4, MAPE, OIP4, Opa-Interacting Protein OIP4, CT130
Entrez ID:
16h
Expression of Immunotherapy Target PRAME in Cancer Correlates with Histone H3 Acetylation and Is Unrelated to Expression of Methylating (DMNT3A/3B) and Demethylating (TET1) Enzymes. (PubMed, J Clin Med)
However, histone acetylation may be one of the epigenetic mechanisms involved in PRAME regulation. Thus, the therapeutic combination of histone deacetylase inhibitors and PRAME immunotherapy merits further investigation.
Journal • IO biomarker • Epigenetic controller
|
DNMT3A (DNA methyltransferase 1) • PRAME (Preferentially Expressed Antigen In Melanoma)
|
PRAME expression
19h
Estrogen Receptor Expression in DICER1-related Lesions is Associated with the Presence of Cystic Components. (PubMed, Am J Surg Pathol)
Lesions not associated with DICER1 pathogenic variants also showed ER-positive stromal cells, including cystic pulmonary airway malformations, cystic renal dysplasia, and simple renal cysts in adult kidneys. ER expression in stromal cells is not a feature of DICER1 perturbation but rather is related to the presence of cystic components.
Journal
|
ER (Estrogen receptor) • PRAME (Preferentially Expressed Antigen In Melanoma) • DICER1 (Dicer 1 Ribonuclease III)
|
ER positive • ER expression • PRAME expression
8d
Characterization of PRAME immunohistochemistry reveals lower expression in pediatric melanoma compared to adult melanoma. (PubMed, Pigment Cell Melanoma Res)
As the available data primarily stem from adult melanoma, and given the clinical and histological distinctions in pediatric melanomas, our understanding of PRAME expression in this specific patient group remains limited. The age-dependent low PRAME expression shown here constrains the use of this marker in pediatric melanoma and may also limit the use of immunotherapeutic strategies against PRAME in young patients.
Journal • IO biomarker
|
PRAME (Preferentially Expressed Antigen In Melanoma)
|
PRAME expression
10d
Androgen Receptor Immunohistochemistry is Superior to PRAME for the Differentiation of Sebaceous Carcinoma From Primary Cutaneous Basaloid Mimics. (PubMed, Am J Dermatopathol)
In contrast, AR was moderately sensitive (66%) and highly specific (92%) for the distinction of SC from basaloid mimics. These attributes, in addition to the nuclear expression of AR in the sebocytic and basaloid components of SC, suggest that AR is superior to PRAME for the diagnosis of SC.
Journal
|
AR (Androgen receptor) • PRAME (Preferentially Expressed Antigen In Melanoma)
|
AR expression • PRAME expression
12d
PRAME Expression in Melanocytic Proliferations in Special Sites. (PubMed, Cutis)
Preferentially expressed antigen of melanoma (PRAME) expression has been characterized as a relatively specific marker of melanoma, but not within the specific population of special-site lesions. This study aimed to determine if PRAME may serve as a specific marker of melanoma within the population of special-sites lesions.
Journal
|
PRAME (Preferentially Expressed Antigen In Melanoma)
|
PRAME expression
1m
Journal
|
PRAME (Preferentially Expressed Antigen In Melanoma)
|
PRAME expression
1m
PRAME Updated: Diagnostic, Prognostic, and Therapeutic Role in Skin Cancer. (PubMed, Int J Mol Sci)
Emerging immunotherapies, including T-cell-based therapies and vaccines targeting PRAME, are being investigated to exploit its cancer-specific expression. Ongoing research into the molecular role and mechanism of action of PRAME in skin cancer continues to open new avenues in both diagnostics and therapeutics, with the potential to transform the management of melanoma and related skin cancers.
Review • Journal • IO biomarker
|
PRAME (Preferentially Expressed Antigen In Melanoma)
|
PRAME expression
2ms
PRAME Is an Effective Tool for the Diagnosis of Nevus-Associated Cutaneous Melanoma. (PubMed, Cancers (Basel))
Pathologists should carefully consider that a PRAME-positive cellular population within the context of a nevus could indicate a CM associated with the nevus. A negative result does not rule out this possibility.
Journal
|
PRAME (Preferentially Expressed Antigen In Melanoma)
|
PRAME expression
2ms
PRAME expression and its prognostic significance in invasive breast carcinoma. (PubMed, Pathol Res Pract)
Our study showed that HER2 positive and TN breast carcinomas more commonly express PRAME than ER positive carcinomas and that PRAME expression shows positive correlation with certain prognostic factors, however PRAME wasn't revealed as an independent prognostic factor in our study. The importance of PRAME expression in breast carcinoma lies in its potential use as an immunotherapeutic target, particularly in patients with limited therapeutic options.
Journal • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PRAME (Preferentially Expressed Antigen In Melanoma)
|
HER-2 positive • ER positive • HER-2 negative • PRAME expression
3ms
Trial completion • Combination therapy
|
HLA-A (Major Histocompatibility Complex, Class I, A) • PRAME (Preferentially Expressed Antigen In Melanoma) • COL6A3 (Collagen Type VI Alpha 3 Chain)
|
PRAME expression
|
cyclophosphamide • Proleukin (aldesleukin) • utomilumab (PF-05082566)
3ms
PRAME Expression: A Target for Cancer Immunotherapy and a Prognostic Factor in Uveal Melanoma. (PubMed, Invest Ophthalmol Vis Sci)
We confirm that PRAME is associated with poor prognosis in UM and has a strong connection with extra copies of 8q. We show that PRAME-specific immunotherapy in an adjuvant setting is promising in treatment of malignancies, including UM.
Journal • IO biomarker
|
PRAME (Preferentially Expressed Antigen In Melanoma)
|
PRAME expression
3ms
Autologous engineered T cell receptor therapy in advanced cancer. (PubMed, Hum Vaccin Immunother)
Of 214 screened patients, 14 were treated (6, IMA101; 8, IMA101 and atezolizumab). Target-specific T cells expanded to constitute up to 78.7% of CD8+ cells. In conclusion, IMA101 was feasible and well tolerated, leveraging the potential of multi-targeted ACT that warrants further investigation.
Review • Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
|
CD8 (cluster of differentiation 8) • CTAG1B (Cancer/testis antigen 1B) • IL2 (Interleukin 2) • MAGEA4 (Melanoma antigen family A, 4) • PRAME (Preferentially Expressed Antigen In Melanoma) • COL6A3 (Collagen Type VI Alpha 3 Chain) • MMP1 (Matrix metallopeptidase 1) • MAGEA1 (MAGE Family Member A1)
|
PRAME expression
|
Tecentriq (atezolizumab) • IMA101
3ms
Expression of Preferentially Expressed Antigen in Melanoma, a Cancer/Testis Antigen, in Carcinoma In Situ of the Urinary Tract. (PubMed, Diagnostics (Basel))
Therefore, PRAME expression may serve as a useful marker for CIS of the urinary tract. Furthermore, PRAME may be a candidate for the novel therapeutic target for standard treatment-refractory CIS patients.
Journal
|
TP53 (Tumor protein P53) • PRAME (Preferentially Expressed Antigen In Melanoma)
|
TP53 expression • PRAME expression
3ms
Shedding light on PRAME expression in dysplastic nevi: a cohort study. (PubMed, Virchows Arch)
Furthermore, a trend of increased PRAME expression from LG-DN to HG-DN was observed. However, the applicability of PRAME in the differential diagnosis of dysplastic lesions remains unclear as can yield conflicting results with morphology, which remains the primary diagnostic tool for melanocytic lesions.
Journal
|
PRAME (Preferentially Expressed Antigen In Melanoma)
|
PRAME expression
4ms
PReferentially Expressed Antigen in MElanoma Expression in Uterine and Ovarian Carcinosarcomas. (PubMed, Int J Gynecol Pathol)
Our results further support PRAME overexpression in gynecologic cancers, including CS with similar expression levels in epithelial and mesenchymal components. PRAME might have a role in epithelial-mesenchymal transition in this group of cancers.
Journal • IO biomarker
|
PRAME (Preferentially Expressed Antigen In Melanoma)
|
PRAME expression
4ms
PRAME induces genomic instability in uveal melanoma. (PubMed, Oncogene)
PRAME expression renders cells susceptible to inhibition of PARP1/2, suggesting increased dependence on alternative base excision repair pathways. These findings reveal a distinct oncogenic function of PRAME that can be targeted therapeutically in cancer.
Journal • PARP Biomarker
|
PRAME (Preferentially Expressed Antigen In Melanoma) • CUL2 (Cullin 2) • SMC1A (Structural Maintenance Of Chromosomes 1A)
|
PRAME expression
4ms
Diagnostic utility of combining PRAME and HMB-45 stains in primary melanocytic tumors. (PubMed, Ann Diagn Pathol)
Our results confirm the superiority of PRAME over HMB-45 in the differential diagnosis of melanocytic tumors. However, combined staining can significantly increase specificity, rendering a benign diagnosis more unlikely in a double 4+ diffuse positivity setting.
Journal
|
PRAME (Preferentially Expressed Antigen In Melanoma)
|
HER-2 expression • PRAME expression
4ms
Characterisation of the protein expression of the emerging immunotherapy targets VISTA, LAG-3 and PRAME in primary uveal melanoma: insights from a southern French patient cohort. (PubMed, Pathology)
PRAME nuclear positivity in melanoma cells was associated with epithelioid cell dominant (>90%) UM histological subtype, higher mitotic numbers and a higher percentage of chromosome 8q gain. This study proposes VISTA as a novel relevant immune checkpoint molecule in primary UM and contributes to confirm LAG-3 and PRAME as potentially important immunotherapy targets in the treatment of UM patients, helping to expand the number of immunotherapy candidate molecules that are relevant to modulate in this aggressive cancer.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • BAP1 (BRCA1 Associated Protein 1) • LAG3 (Lymphocyte Activating 3) • PRAME (Preferentially Expressed Antigen In Melanoma) • VSIR (V-Set Immunoregulatory Receptor)
|
CD8 positive • LAG3 expression • PRAME expression
4ms
Expression of Melan-A in cutaneous granular cell tumours: a diagnostic pitfall. (PubMed, Pathology)
Our study demonstrates that Melan-A expression can be strong and diffuse in a subset of otherwise unequivocal cutaneous GCTs, which may cause diagnostic confusion with malignant melanoma. HMB45 and PRAME did not stain any of the GCTs in our series.
Journal
|
PRAME (Preferentially Expressed Antigen In Melanoma) • MLANA (Melan-A)
|
PRAME expression
4ms
PRAME Expression Is a Useful Tool in the Diagnosis of Primary and Metastatic Dedifferentiated and Undifferentiated Melanoma. (PubMed, Am J Surg Pathol)
Our data emphasize the diagnostic utility of PRAME staining as a first screening tool in the detection and workup of dedifferentiated and undifferentiated melanomas, both in the primary and metastatic settings. PRAME immunohistochemistry is particularly helpful as it is also positive in tumors without a recognizable conventional melanoma precursor and in those associated with desmoplastic melanomas, where PRAME is typically found to be negative.
Journal • Metastases
|
PRAME (Preferentially Expressed Antigen In Melanoma)
|
PRAME expression
5ms
PRAME expression in 137 primary cutaneous melanomas and comparison with 38 related metastases. (PubMed, Pathol Res Pract)
Here, we show statistical analyses on PRAME expression for melanoma with Breslow > 1 mm based on survival rate and long-term follow-up. According to our results, PRAME is a useful immunohistochemical ancillary tool in daily practice diagnosis of melanocytic lesions.
Retrospective data • Journal
|
BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • PRAME (Preferentially Expressed Antigen In Melanoma)
|
BRAF mutation • NRAS mutation • PRAME expression
5ms
Immunohistochemical expression of PRAME in 485 cases of epithelial tubo-ovarian tumors. (PubMed, Virchows Arch)
The clinico-pathologic correlations and survival analysis showed no prognostic significance.The results of our study showed that PRAME is neither prognostic nor a suitable ancillary marker in the differential diagnosis of tubo-ovarian epithelial tumors. Nevertheless, knowledge about the PRAME expression may be important concerning its potential predictive significance, because targeting PRAME as a potential therapeutic option is currently under investigation.
Journal
|
PRAME (Preferentially Expressed Antigen In Melanoma)
|
PRAME expression
5ms
Expression of four cancer-testis antigens in TNBC indicating potential universal immunotherapeutic targets. (PubMed, J Cancer Res Clin Oncol)
MAGE-A4, NY-ESO-1, PRAME and KK-LC-1 are overexpressed in breast cancer, especially in TNBC. Positive expression of MAGE-A4 or PARME may be associated with prolonged DFS. A panel of CTAs is attractive universal targets for immunotherapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CTAG1B (Cancer/testis antigen 1B) • MAGEA4 (Melanoma antigen family A, 4) • PRAME (Preferentially Expressed Antigen In Melanoma) • MAGEA1 (MAGE Family Member A1)
|
PD-L1 expression • PRAME expression
5ms
Immunohistochemistry for PRAME in Dermatopathology. (PubMed, Am J Dermatopathol)
Most metastatic melanomas are positive for PRAME, whereas nodal nevi are not. Numerous studies on PRAME IHC have become available in the past few years with results supporting the value of PRAME IHC as an ancillary tool in the evaluation of melanocytic lesions and providing insights into limitations in sensitivity and specificity as well as possible pitfalls that need to be kept in mind by practicing pathologists.
Journal
|
PRAME (Preferentially Expressed Antigen In Melanoma)
|
PRAME expression
6ms
Molecular and clinicopathological implications of PRAME expression in adult glioma. (PubMed, PLoS One)
PRAME expression statuses may dictate different biological and clinicopathological profiles in IDH-wildtype glioblastoma.
Journal
|
PRAME (Preferentially Expressed Antigen In Melanoma)
|
IDH wild-type • PRAME expression
6ms
Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma (clinicaltrials.gov)
P1/2, N=4, Terminated, Bellicum Pharmaceuticals | N=28 --> 4 | Unknown status --> Terminated; company decision
Enrollment change • Trial termination • Metastases
|
PRAME (Preferentially Expressed Antigen In Melanoma)
|
PRAME expression
|
BPX-701 • rimiducid (AP1903)
6ms
Prognostic Implications of PRAME Expression and Clinicopathological Factors in Sinonasal Mucosal Melanoma: A Single-center Cohort Study of 30 Cases. (PubMed, Anticancer Res)
In sinonasal MM, PRAME IHC staining in ≥70% of cells is associated with significantly lower survival probability. Male sex, pN1 stage, and tumor location in the sinus are also predictive of poorer survival outcomes. These findings highlight the potential prognostic significance of PRAME expression and other clinicopathological factors in MM. Further studies are warranted to validate and expand upon these observations.
Journal
|
BRAF (B-raf proto-oncogene) • SOX10 (SRY-Box 10) • PRAME (Preferentially Expressed Antigen In Melanoma)
|
BRAF V600E • BRAF V600 • PRAME expression
6ms
Cancer vaccine co-targeting PRAME and PD-L1 exerts significant tumor growth inhibition in syngeneic mouse hepatocellular carcinoma models (SITC 2023)
Conclusions The results of this preclinical study clearly highlighted the potential of simultaneously targeting PRAME and PD-L1 by fusion protein vaccination in cancer immunotherapy. Both fusion protein vaccines are currently being evaluated in an aggressive B16/F10 melanoma model.
Preclinical
|
PRAME (Preferentially Expressed Antigen In Melanoma)
|
PRAME expression • PGR expression
6ms
Overcoming tumor heterogeneity – Clinical trial assays to prospectively assign patients customized multiplexed TCR-T cell therapy in Phase 1 (SITC 2023)
Importantly, HLA-A/B/C alleles were almost always lost together, indicating that HLA loss most frequently occurs through haplotype loss, informing a strategy to direct multiplexed TCR-T to the remaining HLA haplotype. Conclusions Overall, these data highlight the importance of a multiplexed TCR-T cell therapy targeting various intact tumor antigens presented on intact HLA alleles in order to effectively address solid tumors.
P1 data • Clinical
|
HLA-B (Major Histocompatibility Complex, Class I, B) • PRAME (Preferentially Expressed Antigen In Melanoma) • HLA-C (Major Histocompatibility Complex, Class I, C)
|
PRAME expression
|
Tempus HLA-LOH assay
|
T-Plex-200-A0201/204-A0201
6ms
Comprehensive Molecular Characterization of a Novel GOLGA4-RAF1 Fusion in a Pediatric Spitz Melanocytoma (ASDP 2023)
In comparison to melanomas, the rarity of this particular fusion in melanocytomas may suggest the possibility of rapid malignant transformation, and patients diagnosed with this entity should be monitored closely. Poster type: Poster Defense
Clinical • Tumor mutational burden
|
TMB (Tumor Mutational Burden) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase) • PRAME (Preferentially Expressed Antigen In Melanoma) • GOLGA4 (Golgin A4) • MLANA (Melan-A)
|
TMB-L • PRAME expression • GOLGA4-RAF1 fusion
6ms
A case of melanoma arising in a cellular blue nevus with numerous chromosomal abnormalities (ASDP 2023)
Melanoma arising in cellular blue nevi more frequently demonstrates multiple chromosomal aberrations, which are also more likely to be complex, in comparison to atypical cellular blue nevi. Poster type: Poster Defense
Clinical
|
BAP1 (BRCA1 Associated Protein 1) • PRAME (Preferentially Expressed Antigen In Melanoma) • MLANA (Melan-A)
|
MYC rearrangement • PRAME expression
6ms
Undifferentiated Metastatic Melanoma Involving the Parotid Gland; the Value of Genetic Analysis (ASDP 2023)
It also enhances our understanding of melanoma as a great mimicker and a tumor with various immunophenotypes. The utilization of molecular analysis, together with the clinical history, is helpful in reaching an accurate diagnosis in poorly differentiated tumors that lack conventional immunohistochemical markers of melanoma.  Poster type: Poster Defense
Metastases
|
BRAF (B-raf proto-oncogene) • SOX10 (SRY-Box 10) • PRAME (Preferentially Expressed Antigen In Melanoma) • MLANA (Melan-A) • SALL4 (Spalt Like Transcription Factor 4)
|
BRAF V600E • BRAF V600 • PRAME expression
6ms
The Expanding Role of Next Generation Sequencing in Distinguishing De-differentiated Melanoma from Pleomorphic Dermal Sarcoma (ASDP 2023)
Even focal expression of a melanocytic marker should cast doubt on a diagnosis of PDS and raise the possibility of de-differentiated melanoma, since therapy and outcomes are significantly different. Poster type: Poster Defense
Next-generation sequencing
|
BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • TERT (Telomerase Reverse Transcriptase) • SOX10 (SRY-Box 10) • PRAME (Preferentially Expressed Antigen In Melanoma) • CD31 (Platelet and endothelial cell adhesion molecule 1) • MLANA (Melan-A) • TP63 (Tumor protein 63) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
|
TP53 mutation • BRAF V600E • NRAS mutation • NRAS Q61 • NRAS Q61R • NRAS Q61L • PRAME expression
6ms
PRAME expression is a useful tool in the diagnosis of primary and metastatic dedifferentiated and undifferentiated melanoma (ASDP 2023)
PRAME immunohistochemistry is particularly helpful as it is also positive in tumors without a recognizable conventional melanoma precursor and in those associated with desmoplastic melanomas, where PRAME is typically negative. Poster type: Poster Defense
Metastases
|
PRAME (Preferentially Expressed Antigen In Melanoma)
|
PRAME expression
6ms
Perineuriomatous Melanocytic Nevi: 27 Cases Including a Novel Myxoid Variant (ASDP 2023)
Our data suggest that perineuriomatous melanocytic nevi remain unfamiliar and diagnostically challenging. Perineuriomatous differentiation can be found in melanocytic nevi of both conventional and Spitz lineage. Dramatic myxoid change can occasionally be observed.
Clinical
|
PRAME (Preferentially Expressed Antigen In Melanoma)
|
PRAME expression
6ms
Journal
|
BAP1 (BRCA1 Associated Protein 1) • PRAME (Preferentially Expressed Antigen In Melanoma)
|
PRAME expression
7ms
PRAME/MELAN-A double immunostaining as a diagnostic tool for conjunctival melanocytic lesions: A South American experience. (PubMed, Pathol Res Pract)
PRAME/MELAN-A double immunostain is particularly useful to differentiate benign from malignant conjunctival melanocytic lesions.
Journal
|
PRAME (Preferentially Expressed Antigen In Melanoma) • MLANA (Melan-A)
|
PRAME expression
7ms
PRAME expression in cutaneous melanoma does not correlate with disease-specific survival. (PubMed, J Cutan Pathol)
Ki-67 is an independent prognostic marker; although increased PRAME expression correlates with the Ki-67 proliferation index and mitotic rate, PRAME is not an independent prognostic marker for cutaneous melanoma. PRAME and Ki-67 are useful ancillary tools for distinguishing benign from malignant melanocytic lesions.
Journal
|
PRAME (Preferentially Expressed Antigen In Melanoma)
|
PRAME expression
7ms
PRAME expression and its relationship between clinicopathological parameters and immunological markers in melanoma: an in-silico analysis (ECP 2023)
Conclusion PRAME expression was associated with immune infiltration and immune modulator or immune check points genes. Our results suggested that it can be a potential biomarker for predicting immunotherapy response in melanoma.
Clinical • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • PD-L2 (Programmed Cell Death 1 Ligand 2) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule) • PRAME (Preferentially Expressed Antigen In Melanoma)
|
PRAME expression